Myles Greenberg
Partner @ CHL Medical Partners
Salt Lake City, United States
Myles Greenberg is a Series B investor at CHL Medical Partners in Salt Lake City focused on Biotechnology and Medical. Myles Greenberg is based out of Salt Lake City, Utah and is the President and CEO of InCarda Therapeutics. Myles previously worked at Alucent Biomedical, Inc. as a President and CEO. Myles Greenberg attended Harvard Business School.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Myles Greenberg invests in
Stages Myles Greenberg invests in
Countries Myles Greenberg invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (36%)
- Medical 3 (27%)
- Health Care 3 (27%)
- SaaS 1 (9%)
- Biopharma 1 (9%)
Stage
- Series B 3 (27%)
- Series A 1 (9%)
- Series C 1 (9%)
- Series D 1 (9%)
- Funding Round 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $200M / Private Equity / Aug 04, 2014 | ||
| Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $5M / Debt Financing / Jun 24, 2014 | ||
| Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $55M / Private Equity / Jun 25, 2013 | ||
| Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England BaptistHospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows. | $5M / Series B / May 16, 2012 | ||
| Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $45M / Jan 24, 2012 | ||
| Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England BaptistHospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows. | $7.5M / Series A / Nov 04, 2010 | ||
| Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $14M / Series B / Nov 01, 2010 | ||
| Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $15.5M / Series D / Oct 20, 2009 | ||
| Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $33M / Jan 01, 2009 | ||
| Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $12M / Series C / Jul 15, 2008 | ||
| See all 11 investments → | |||
Co-Investors
About CHL Medical Partners
CHL Medical Partners, an American venture capital firm, invests in biotechnology, molecular diagnostic, and medical device companies.
CHL Medical Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Timothy F.Howe
Founder & Partner
|
|||
Jeffrey J. Collinson
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Myles Greenberg invest in?
Myles Greenberg invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Myles Greenberg?
Public channels for Myles Greenberg include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Myles Greenberg last invest?
The most recent investment recorded for Myles Greenberg closed in Aug 2014. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
